DrugBiological
Otilimab clinical trials
Also written GSK3196165 and MOR103.
- studies test it
- 12
- open now
- 0
- in phase 3
- 4
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 7
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Studies
Open first, then newest update. How each study uses Otilimab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related DiseaseCompletedPhase 2GlaxoSmithKlineNCT04376684Written as Otilimab
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateCompletedPhase 3GlaxoSmithKlineNCT03980483Written as GSK3196165 (Otilimab)
- Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)TerminatedPhase 3GlaxoSmithKlineNCT04333147Written as Otilimab (GSK3196165)
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)TerminatedPhase 3GlaxoSmithKlineNCT03970837Written as GSK3196165 (Otilimab)
- Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) InhibitorsCompletedPhase 3GlaxoSmithKlineNCT04134728Written as GSK3196165 (Otilimab)
- A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of OtilimabWithdrawnPhase 1GlaxoSmithKlineNCT05304130Written as Otilimab
- Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid ArthritisCompletedPhase 2GlaxoSmithKlineNCT02799472Written as GSK3196165
- A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand OsteoarthritisCompletedPhase 2GlaxoSmithKlineNCT02683785Written as GSK3196165
- Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid ArthritisCompletedPhase 2GlaxoSmithKlineNCT02504671Written as GSK3196165
- Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid ArthritisCompletedPhase 1/2GlaxoSmithKlineNCT03028467Written as GSK3196165 Dose 1
- Phase Ib Study to Evaluate MOR103 in Multiple SclerosisCompletedPhase 1/2MorphoSys AGNCT01517282Written as MOR103
- Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid ArthritisCompletedPhase 1/2MorphoSys AGNCT01023256Written as MOR103
Codes
What other systems call Otilimab · ClinicalTrials.gg INT000272
- MeSH (NLM) C000599766OtilimabOne source NLM
- UNII (FDA) Y8127R3VCHOTILIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q56291893otilimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170271OtilimabOne source FDA
- DrugBank DB06303One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599766 | Otilimab | One source NLM |
| UNII (FDA) | Y8127R3VCH | OTILIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q56291893 | otilimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170271 | Otilimab | One source FDA |
| DrugBank | DB06303 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.